Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;7(2):85-97.
doi: 10.1177/23971983221086343. Epub 2022 Apr 19.

Management of scleroderma gastrointestinal disease: Lights and shadows

Jenice X Cheah  1 , Dinesh Khanna  2 , Zsuzsanna H McMahan  3
Affiliations
Review

Management of scleroderma gastrointestinal disease: Lights and shadows

Jenice X Cheah et al. J Scleroderma Relat Disord. 2022 Jun.

Abstract

Gastrointestinal symptoms affect the great majority of patients with systemic sclerosis. Management of these complications is often challenging as any region of the gastrointestinal tract may be involved, and significant heterogeneity exists in clinical presentation, kinetics, and outcomes. Here, we highlight new findings relevant to the management of systemic sclerosis-related gastrointestinal disease (lights) and consider areas that we have yet to elucidate (shadows).

Keywords: GI complications; SSc-related gastrointestinal disease; Systemic sclerosis; dysmotility; gastrointestinal; management; scleroderma complications.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Action of pro-motility agents at the GI tract.
See this image and copyright information in PMC

References

    1. Gabrielli A, Avvedimento EV, Krieg T. Mechanisms of disease: scleroderma. N Engl J Med 2009; 360(19): 1989–2003. - PubMed
    1. Nagaraja V, McMahan ZH, Getzug T, et al. Management of gastrointestinal involvement in scleroderma. Curr Treat Options Rheumatol 2015; 1(1): 82–105. - PMC - PubMed
    1. Jaovisidha K, Csuka ME, Almagro UA, et al. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum 2005; 34(4): 689–702. - PubMed
    1. Dein E, Kuo PL, Hong YS, et al. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum 2019; 49(3): 405–410. - PMC - PubMed
    1. Shah AA, Wigley FM. Often forgotten manifestations of systemic sclerosis. Rheum Dis Clin North Am 2008; 34(1): 221–238, ix. - PubMed